Sangamo Therapeutics recently reported detailed data from its completed registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease, alongside confirmation that the ...
Regenxbio Inc. (RGNX) has made good progress with respect to its pipeline, especially in light of the fact that it has a strategy around being able to have five gene therapies in late-stage testing or ...
The application process is underway for River Parishes Community College's Process Technology Express Pathway program. The PTEC program is an accelerated class designed for people with prior academic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results